These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 27736041)

  • 1. Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study.
    Choi NK; Solomon DH; Tsacogianis TN; Landon JE; Song HJ; Kim SC
    J Bone Miner Res; 2017 Mar; 32(3):611-617. PubMed ID: 27736041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Cataract Surgery and Age-Related Macular Degeneration After Initiation of Denosumab vs Zoledronic Acid for Osteoporosis: A Multi-Database Cohort Study.
    Lee H; Jin Y; Roh M; Tsacogianis TN; Park S; Choi NK; Kim SC
    Drugs Aging; 2020 Apr; 37(4):311-320. PubMed ID: 32026309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness and safety outcomes between denosumab and bisphosphonate in South Korea.
    Park C; Kim C; Park RW; Jeon JY
    J Bone Miner Res; 2024 Aug; 39(7):835-843. PubMed ID: 38722817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of denosumab versus zoledronic acid in the older adults with osteoporosis: a meta-analysis of cohort studies.
    Li W; Ning Z; Yang Z; Fan T; Yao M; Zhang W; Wang M; Wen A; Wang J
    Arch Osteoporos; 2022 Jun; 17(1):84. PubMed ID: 35715524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
    Kajizono M; Sada H; Sugiura Y; Soga Y; Kitamura Y; Matsuoka J; Sendo T
    Biol Pharm Bull; 2015; 38(12):1850-5. PubMed ID: 26632176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab versus zoledronic acid in elderly patients after hip fracture.
    Kim SJ; Kim JW; Lee DW
    J Orthop Surg (Hong Kong); 2022; 30(3):10225536221147082. PubMed ID: 36541833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy, adverse effects, and cost of zoledronic acid and denosumab in the treatment of osteoporosis.
    Sheedy KC; Camara MI; Camacho PM
    Endocr Pract; 2015 Mar; 21(3):275-9. PubMed ID: 25370317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of denosumab, teriparatide, and zoledronic acid among frail older adults: a retrospective cohort study.
    Zullo AR; Lee Y; Lary C; Daiello LA; Kiel DP; Berry SD
    Osteoporos Int; 2021 Mar; 32(3):565-573. PubMed ID: 33411003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence with denosumab and zoledronic acid among older women: a population-based cohort study.
    Tremblay É; Perreault S; Dorais M
    Arch Osteoporos; 2016 Dec; 11(1):30. PubMed ID: 27679503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world effectiveness of osteoporosis treatments in Germany.
    O'Kelly J; Bartsch R; Kossack N; Borchert J; Pignot M; Hadji P
    Arch Osteoporos; 2022 Aug; 17(1):119. PubMed ID: 36044096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fracture risk and zoledronic acid therapy in men with osteoporosis.
    Boonen S; Reginster JY; Kaufman JM; Lippuner K; Zanchetta J; Langdahl B; Rizzoli R; Lipschitz S; Dimai HP; Witvrouw R; Eriksen E; Brixen K; Russo L; Claessens F; Papanastasiou P; Antunez O; Su G; Bucci-Rechtweg C; Hruska J; Incera E; Vanderschueren D; Orwoll E
    N Engl J Med; 2012 Nov; 367(18):1714-23. PubMed ID: 23113482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Incident Atrial Fibrillation With Zoledronic Acid Versus Denosumab: A Propensity Score-Matched Cohort Study.
    D'Silva KM; Cromer SJ; Yu EW; Fischer M; Kim SC
    J Bone Miner Res; 2021 Jan; 36(1):52-60. PubMed ID: 33137852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access.
    Burden AM; Tadrous M; Calzavara A; Cadarette SM
    Osteoporos Int; 2015 May; 26(5):1525-33. PubMed ID: 25603794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.
    Raje N; Vadhan-Raj S; Willenbacher W; Terpos E; Hungria V; Spencer A; Alexeeva Y; Facon T; Stewart AK; Feng A; Braun A; Balakumaran A; Roodman GD
    Blood Cancer J; 2016 Jan; 6(1):e378. PubMed ID: 26745852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Various Anti-Osteoporosis Drugs on All-Cause Mortality After Hip Fractures: A Nationwide Population Study.
    Tai TW; Hwang JS; Li CC; Hsu JC; Chang CW; Wu CH
    J Bone Miner Res; 2022 Aug; 37(8):1520-1526. PubMed ID: 35689432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparability of Osteoporosis Treatment Groups Among Female Medicare Beneficiaries in the United States.
    Kim M; Lin TC; Arora T; Zhao H; Balasubramanian A; Stad RK; O'Kelly J; Spangler L; Bradbury BD; Curtis JR
    J Bone Miner Res; 2023 Jun; 38(6):829-840. PubMed ID: 37088886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.
    Curtis JR; Xie F; Yun H; Saag KG; Chen L; Delzell E
    Arthritis Rheumatol; 2015 Jun; 67(6):1456-64. PubMed ID: 25708920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Saridakis ZG; Digkas D; Bisbinas I; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Osteoporos Int; 2015 Oct; 26(10):2521-7. PubMed ID: 25990355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.